NGC Update Service: January 29, 2018


January 29, 2018

New This Week

Published Guideline Summaries

American Society for Reproductive Medicine

Withdrawn Guideline Summaries

The guideline summaries listed below have been withdrawn from the NGC Web site because they no longer meet the NGC Inclusion Criteria. See the Guideline Summaries Archive for a complete list of summaries that have been withdrawn from NGC.

American Academy of Neurology

  • Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.

Genetic Metabolic Dietitians International & Southeast Regional Newborn Screening and Genetics Consortium

  • Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach.

National Collaborating Centre for Primary Care

  • The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care.

National Guideline Alliance

  • Antibiotics for early-onset neonatal infection. Antibiotics for the prevention and treatment of early-onset neonatal infection.
  • Autism: recognition, referral, diagnosis and management of adults on the autism spectrum.
  • Ectopic pregnancy and miscarriage: diagnosis and initial management in early pregnancy of ectopic pregnancy and miscarriage.
  • Metastatic spinal cord compression. Diagnosis and management of adults at risk of and with metastatic spinal cord compression.
  • Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients.
  • Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults.
  • Spasticity in children and young people with non-progressive brain disorders: management of spasticity and co-existing motor disorders and their early musculoskeletal complications.

National Guideline Centre

  • Headaches: diagnosis and management of headaches in young people and adults.
  • Infection. Prevention and control of healthcare-associated infections in primary and community care.
  • Lower limb peripheral arterial disease: diagnosis and management.
  • Osteoporosis: assessing the risk of fragility fracture.
  • Psoriasis: the assessment and management of psoriasis.
  • Urinary incontinence in neurological disease. Management of lower urinary tract dysfunction in neurological disease.

National Health and Medical Research Council

  • Clinical practice guideline for the management of borderline personality disorder.

National Institute for Health and Care Excellence (NICE)

  • Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122).
  • Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer.
  • Boceprevir for the treatment of genotype 1 chronic hepatitis C.
  • Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation.
  • Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70).
  • Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
  • Eribulin for the treatment of locally advanced or metastatic breast cancer.
  • Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis.
  • Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma.
  • Ivabradine for treating chronic heart failure.
  • Mannitol dry powder for inhalation for treating cystic fibrosis.
  • Pharmalgen for the treatment of bee and wasp venom allergy.
  • Sickle cell acute painful episode: management of an acute painful sickle cell episode in hospital.
  • Telaprevir for the treatment of genotype 1 chronic hepatitis C.
  • Tocilizumab for the treatment of rheumatoid arthritis (rapid review of technology appraisal guidance 198).
  • Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.

National Kidney Foundation

  • KDOQI clinical practice guideline for diabetes and CKD: 2012 update


G-I-N Conference

The Guidelines International Network (G-I-N) 2018 Conference will take place from September 11-14, 2018 in Manchester. The theme is "Why We Do What We Do: The Purpose and Impact of Guidelines." Registration is open. For more information, visit the G-I-N Conference Web site.

U.S. Food and Drug Administration (FDA) Advisory

January 16, 2018: Varubi (rolapitant) Injectable Emulsion: Health Care Provider Letter - Anaphylaxis and Other Serious Hypersensitivity Reactions: Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported in the postmarketing setting, some requiring hospitalization. These reactions have occurred during or soon after the infusion of Varubi (rolapitant) injectable emulsion. Most reactions have occurred within the first few minutes of administration. Symptoms of anaphylaxis can include wheezing or difficulty breathing; swelling of the face or throat; hives or flushing; itching; abdominal cramping, abdominal pain or vomiting; back pain or chest pain; hypotension or shock.

Health Awareness Topics: January 2018

How to Participate

Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.

Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.

NGC's Sister Resource

Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).